30 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 30 of 30 clinical reviews.
A clinical review of combining 5-HTP with tesamorelin (Egrifta), covering pharmacokinetic and pharmacodynamic interactions, serotonin syndrome risk, GH-axis effects, monitoring, and practical dosing guidance.
What is known and not established about combining alpha-lipoic acid with tesamorelin (Egrifta), including plausible hypoglycemia and thyroid-axis interactions, and what to verify with a clinician or pharmacist.
A guide to the ashwagandha and tesamorelin (Egrifta) interaction: mechanism, cortisol modulation, thyroid effects, monitoring, and clinical safety guidance.
A clinical review of the berberine-tesamorelin interaction: pharmacokinetics, blood glucose effects, CYP3A4 concerns, and practical guidance for patients on Egrifta.
A guide to the caffeine and tesamorelin interaction: pharmacokinetics, cortisol and glucose effects, blood pressure monitoring, and practical dosing guidance for patients on Egrifta.
What is known and not established about combining calcium supplements with Egrifta SV (tesamorelin) in HIV-associated lipodystrophy, including bone and IGF-1 considerations, and where a pharmacist should be consulted before dosing decisions.
A guide to combining CoQ10 with Egrifta (tesamorelin): interaction mechanism, safety data, dosing timing, and monitoring recommendations for people on HIV-associated lipodystrophy therapy.
A guide to combining creatine supplementation with tesamorelin (Egrifta), covering the creatinine-elevation concern, renal monitoring, pharmacokinetics, and practical dosing guidance.
A guide covering the folate, tesamorelin interaction, MTHFR considerations, pharmacokinetics, dosing timing, and monitoring for patients on Egrifta.
Evidence-based guide on combining ginseng supplements with tesamorelin (Egrifta), covering interaction mechanisms, glucose effects, monitoring, and dose-separation strategies.
A guide to combining glutathione supplements with tesamorelin (Egrifta), covering mechanisms, pharmacokinetic interactions, safety monitoring, and dosing guidance.
A clinical review of glycine and tesamorelin (Egrifta) co-administration: mechanisms, interaction type, glycemic monitoring, dosing timing, and when to contact your prescriber.
A guide covering the hepatotoxicity risk, CYP enzyme interactions, and monitoring considerations when combining green tea extract or EGCG with Egrifta (tesamorelin) for HIV-associated lipodystrophy.
A guide to combining L-theanine with tesamorelin (Egrifta), covering pharmacokinetic and pharmacodynamic interaction risk, dosing windows, monitoring, and clinical safety data.
A guide to combining lion's mane mushroom with tesamorelin (Egrifta), covering pharmacokinetic and pharmacodynamic interaction risks, NGF signaling overlap, bleeding considerations, and monitoring steps.
A board-reviewed guide to the magnesium, tesamorelin interaction: mechanism, safety evidence, monitoring parameters, and practical dosing guidance for HIV-associated lipodystrophy patients.
What is established, what is plausible, and what is unproven about combining melatonin with tesamorelin (Egrifta) for HIV-associated lipodystrophy, including the glucose-related pharmacodynamic concern and a verification checklist for clinicians and pharmacists.
A guide to combining NAC with tesamorelin (Egrifta): mechanism-based interaction analysis, pharmacokinetic vs pharmacodynamic considerations, dosing timing, monitoring parameters, and clinical decision guidance.
A clinical review of the omega-3 and tesamorelin combination: pharmacodynamic triglyceride overlap, antiplatelet considerations, monitoring parameters, and practical guidance for patients on Egrifta for HIV-associated lipodystrophy.
A clinical review of quercetin and tesamorelin (Egrifta) interactions, covering CYP3A4 pharmacokinetics, safety evidence, dosing strategy, and monitoring guidance for HIV-associated lipodystrophy patients.
A guide to the reishi mushroom and tesamorelin interaction: mechanism, immune modulation, anticoagulant risk, monitoring, and practical guidance for people on Egrifta.
A clinical breakdown of the resveratrol and tesamorelin interaction: pharmacokinetics, CYP3A4 overlap, estrogenic effects on GH signaling, monitoring guidance, and what to do if you are already taking both.
A guide to the tesamorelin and rhodiola interaction: mechanism, risk level, monitoring steps, and when to call your prescriber.
Evidence-based guide on combining saw palmetto with tesamorelin (Egrifta). Covers interaction mechanisms, safety data, monitoring recommendations, and dose-separation strategies.
A clinical review of the St. John's Wort and tesamorelin (Egrifta) interaction, covering CYP3A4 induction, IGF-1 monitoring, and what to do if you are already taking both.
A clinical guide to the turmeric/curcumin and tesamorelin interaction: mechanism, safety evidence, dosing considerations, and monitoring recommendations for patients on Egrifta.
Evidence-based guide on combining vitamin B12 supplements with tesamorelin (Egrifta). Covers interaction risk, metformin-related B12 depletion, neuropathy overlap, dosing, and monitoring.
A board-reviewed clinical guide on combining vitamin B6 with Egrifta (tesamorelin): interaction mechanisms, safe dose ranges, monitoring requirements, and when to call your prescriber.
A guide on combining vitamin D supplementation with Egrifta (tesamorelin), covering interaction mechanisms, safety, monitoring, and dosing guidance for HIV-associated lipodystrophy patients.
Evidence-based guide on combining zinc supplements with tesamorelin (Egrifta). Covers pharmacokinetic and pharmacodynamic profiles, dose-separation strategy, copper balance risks, and clinical monitoring.